Fusion of Biocina and Novacina: A new giant in the biopharm!

Fusion of Biocina and Novacina: A new giant in the biopharm!

Adelaide, Südaustralien, Australien - The Biocina and Novacina have announced a strategic merger today that could revolutionize the international CDMO industry. The union of the two companies is continued under the name Biocina and aims to offer a comprehensive portfolio of services in the biopharmaceutical and small molecular order production. This merger pursues the goal of operating the increasing need for integrated production solutions for customers around the world, especially in the USA, Europe, Asia and Australia, such as Oots.at reported .

synergies and expertise bundle

The merging of the first-class know-how of Biocina from Adelaide, South Australia, in process development for microbial and mRNA modalities with the state-of-the-art sterile filling system from Novacina in Perth aims to maximize the efficiency and quality of the production solutions. Over 600 biopharmaceutical products have already been produced in these systems. The leadership of Mark W. Womack, who acts as managing director and looks back on a long-term success story in the industry, is intended to further strengthen customer orientation and operational excellence, while the company tirelessly works to meet the strict regulatory requirements, such as biocina.com has .

BIOCINA offers a wide range of services that range from cell line development to analytical and formulation development to clinical and commercial GMP production. With a track record in the approval of pharmaceuticals by global supervisory authorities, including the FDA and the EMA, Biocina is well positioned in order to act in a rapidly changing market as a reliable partner for pharmaceutical developers. The company emphasizes that Australia is optimal with attractive tax breaks to support development and production.